(Bloomberg Gadfly) -- Things are about to get awkward formakers of drugs targeting multiple sclerosis.
On Thursday afternoon, House Democrats sent letters toprominent biopharma companies that sell MStreatments including Biogen Inc., Novartis AG, Roche Holding AG,and Sanofi, demanding a variety of information about the large and,according to the letters, often seemingly concerted price hikesthey have taken as part of an "in-depth investigation." As would beexpected, the news sparked a decline in the drugmakers' shares.
The investigation will throw an unwelcome spotlight on thesecompanies' pricing practices and force the release of a lot ofdocuments they'd rather not make public. But this is a pageantwe've seen before. As uncomfortable as it will be for thedrugmakers, it may not result in much lastingdamage.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
